Tirzepatide Effective on Cardiometabolic Abnormalities, Metabolic Syndrome in T2D – American College of Cardiology
The dual GIP/GLP-1 receptor agonist tirzepatide is effective in improving cardiometabolic abnormalities and resolving metabolic syndrome (MetS) in patients with type 2 diabetes (T2D) compared to placebo or standard antihyperglycemic therapies according to a new pooled analysis published in JACC. In the meta-analysis, Arya Aminorroaya, MD, MPH, et al., synthesized individual participant data from 7,805 participants with T2D from seven phase 3 randomi zed clinical trials across the Asia-Pacific, South
